

Patient engagement (PE) in publications

ISMPP PATIENT ENGAGEMENT TASKFORCE (PETF)

Strategic Plan

2024-2025



International Society for Medical Publication Professionals

Strategic plan: Approach

Mission and vision

Opportunities and challenges

Strategic goals

Focus and tactical plan





The mission and vision

MISSION

VISION

To facilitate patient engagement throughout the publication lifecycle

Patients
established as a
key collaborator
in industrysponsored
publications





PE in publications: Opportunities identified by the PETF

Patients can play a key role as collaborators in many aspects of medical publications including:

For specific publication plans

- As idea generators and planners: Conceptualizing and planning publications
- As content collaborators/creators: Collaborating, co-creating, and authoring publications
- As readers and sharers: Disseminating and digesting publications

As advisors to guide our profession

- Guiding/advising pharma industry regarding involving patients in publications
- Guiding/advancing ISMPP as our professional body
- Guiding/advising the discipline of medical publishing in general through contribution to industry-wide standards and guidelines, e.g. Good Publications Practice (GPP)





PE in publications: Key challenges identified by the PETF

Lack of awareness of, and evidence for, the value

Lack of awareness and understanding of the opportunities by both patients and industry

Lack of understanding of the patient perspective regarding their engagement in publications

Concerns about engaging with patients compliantly within a highly regulated environment

Potential for engagement to be perceived as tokenistic

Finding the right patients to partner with

Lack of expert patients with specific skills who want to partner





Strategic goals for the PETF

Communicate the rationale, evidence base, and existing resources for PE in publications to all key stakeholders

Understand and address barriers to PE in publications for key stakeholders

Identify specific opportunities to involve patients throughout the publication lifecycle

Provide guidance/tools on best practices for including patients in specific activities throughout the lifecycle

Embed patients as key stakeholders in the evolution of medical publications by including them in ISMPP initiatives

Provide a forum for interactive discussion regarding PE in publications

Establish ISMPP as a leader in the evolution of patient engagement in publications





Tactical plan to achieve the strategic goals for the PETF

Focus groups

Insights

To better understand the unmet needs of the ISMPP community

Value and metrics

To explore ways to measure and communicate the value of PE in publications

Awareness and communication

To raise awareness of PE in publications including existing resources

Guidance and training

To develop new resources to facilitate PE in publications

ISMPP partnerships

To establish ISMPP as a as a leader in the evolution of patient engagement in publications

5 focus groups were established within the PETF

Each focus groups was empowered to drive their own initiatives to meet the specific goals

Focus groups were encouraged to provide a regular update to the broader taskforce during scheduled calls





Appendix: Points to note regarding scope

Where "patients" are referred to, this can also include family, caregivers, patient advocates, and patient groups

This taskforce is specific to industry-sponsored publications to reflect the remit of ISMPP

Patient engagement in publications is often dependent on upstream events such as involvement in evidence generation, but this is beyond the scope

Patient engagement in publishing (including peer-review) is important, but influencing this is beyond the scope of this taskforce





Appendix: Key stakeholders

Expert patient partners (advisors)

Pharma – publications/Medical affairs

Professional medical writers/ editors (agency, freelance)

Enthusiastic potential patient collaborators

Pharma – compliance/legal

Pharma – all (clinical, R&D etc)

Professional societies (e.g., ISMPP leadership)

Patient advocacy groups

Pharma – senior management/ budget holder

All HCPs/researchers including academic institutions

Lay audiences

Publishers/peer reviewers

